

24. (New) The ribozyme of claim 23, wherein said ribozyme comprises the sequence of SEQ ID NO:7 (RZ1).

25. (New) The ribozyme of claim 24, wherein said ribozyme has the sequence of SEQ ID NO:7 (RZ1).

26. (New) The ribozyme of claim 23, wherein said ribozyme comprises the sequence of SEQ ID NO:11 (RZ2).

27. (New) The ribozyme of claim 26, wherein said ribozyme has the sequence of SEQ ID NO:11 (RZ2).

28. (New) The ribozyme of claim 26, wherein said ribozyme is formulated in a liposome.

29. (New) A nucleic acid that encodes a ribozyme in accordance with claim 23.

30. (New) The nucleic acid of claim 29, wherein said nucleic acid encodes a ribozyme that comprises the sequence of SEQ ID NO:7 (RZ1).

31. (New) The nucleic acid of claim 29, wherein said nucleic acid encodes a ribozyme that comprises the sequence of SEQ ID NO:11 (RZ2).

32. (New) The nucleic acid of claim 29, wherein said nucleic acid further comprises a promoter.

33. (New) The nucleic acid of claim 29, wherein said nucleic acid is comprised within a recombinant vector.

34. (New) The nucleic acid of claim 33, wherein said nucleic acid is comprised within a recombinant viral vector.

35. (New) The nucleic acid of claim 34, wherein said nucleic acid is comprised within a recombinant adenoviral vector, adeno-associated viral vector or retroviral vector.

36. (New) An expression vector that expresses a ribozyme in accordance with claim 23.

37. (New) The expression vector of claim 36, wherein said vector expresses a ribozyme that comprises the sequence of SEQ ID NO:7 (RZ1).

38. (New) The expression vector of claim 36, wherein said vector expresses a ribozyme that comprises the sequence of SEQ ID NO:11 (RZ2).

39. (New) The expression vector of claim 36, wherein said vector provides 5' capping and polyadenylation of the expressed ribozyme.

40. (New) A method for reducing estrogen receptor activity, comprising providing an effective amount of a ribozyme in accordance with claim 23 to estrogen receptor-containing cultured cells.

41. (New) The method of claim 40, wherein the estrogen-dependent proliferation of said cells is inhibited.

42. (New) A method for inhibiting estrogen-dependent cell proliferation, comprising administering a ribozyme in accordance with claim 23 to estrogen receptor-containing cells *in vitro* in an amount effective to inhibit proliferation of said cells.

43. (New) The method of claim 42, wherein said ribozyme comprises the sequence of SEQ ID NO:7 (RZ1).

44. (New) The method of claim 42, wherein said ribozyme comprises the sequence of SEQ ID NO:11 (RZ2).

45. (New) The method of claim 42, wherein said ribozyme is administered to said cells in a liposome.

46. (New) The method of claim 42, wherein a vector that expresses said ribozyme is administered to said cells.